Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1779 | Hydroxychloroquine + Metabolic cofactor supplementation Wiki | 1.00 |
| drug4251 | Vitamin D Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012141 | Respiratory Tract Infections NIH | 0.16 |
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
This open label, randomized, controlled, investigator-initiated, multi-centre trial aims to establish metabolic improvements in COVID-19 subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine plus standard therapy. The primary objective is to assess the clinical efficacy of the combination of metabolic cofactors supplementation and hydroxychloroquine in COVID-19 patients.
Description: The clinical efficacy will be evaluated by comparing the proportion of patients who were hospitalised during the course of disease until 14 days after the initial diagnosis of Covid-19.
Measure: The evaluation of clinical efficacy of the combination of metabolic cofactor supplementation and hydroxychloroquine Time: 14 daysDescription: Number/characteristics of Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment due to study drug from baseline until the end of study.
Measure: Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment Time: 14 daysDescription: Chest imaging will be documented at baseline visit.
Measure: Chest Tomography Time: 1 dayDescription: Change in heart rate will be measured at baseline visit.
Measure: ECG Measurement Time: 1 dayDescription: Complete blood count includes number of blood cells and concentration of hemoglobin. Complete blood count will be performed to measure possible toxic effects of the metabolic cofactors supplementation and hydroxychloroquine combination on hematological system.
Measure: Change of complete blood count from baseline Time: 14 daysDescription: Clinical evaluation of ALT levels from baseline until the end of study.
Measure: Changes in alanine aminotransferase (ALT) levels from baseline Time: 14 daysDescription: Clinical evaluation of AST levels from baseline until the end of study.
Measure: Changes in aspartate aminotransferase (AST) levels from baseline Time: 14 daysDescription: Clinical evaluation of CRP levels from baseline until the end of study.
Measure: Changes in C-reactive protein (CRP) levels from baseline Time: 14 daysDescription: Clinical evaluation of creatinine levels from baseline until the end of study.
Measure: Changes in creatinine levels from baseline Time: 14 daysDescription: Clinical evaluation of D-dimer levels from baseline until the end of study.
Measure: Changes in D-dimer levels from baseline Time: 14 daysDescription: Clinical evaluation of ferritin levels from baseline until the end of study.
Measure: Changes in ferritin levels from baseline Time: 14 daysDescription: Clinical evaluation of triglycerides levels from baseline until the end of study.
Measure: Changes in triglycerides levels from baseline Time: 14 daysDescription: Clinical evaluation of LDH levels from baseline until the end of study.
Measure: Changes in LDH levels from baseline Time: 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports